Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (Vitaeris)

Protocol Name: IMAGINE: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Sponsor: Vitaeris

Indication: Post Transplant – Chronic Active Antibody Mediated Rejection

Primary Investigator: Bernard Fischbach, MD

Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

DETAILS >